Abstracts Archive - Page 143 of 2607 - ACR Meeting Abstracts

Abstract Number: 0116 • ACR Convergence 2025
Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI
Chun Li¹, Jianping Guo², Yangyi Fan¹, Yu Kang¹ and Xiaodan Hu¹, ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking University People's Hospital, Beijing, Beijing, China
Background/Purpose: Cerebrovascular diseases are common and severe neurological complications in antiphospholipid syndrome (APS). However, few studies focused on cerebral small vessel disease (cSVD) in APS.…
Abstract Number: 0157 • ACR Convergence 2025
Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
Lesley Jackson¹, Nicole Wright², Rahima Begum³, Fazlur Rahman¹, Rena Patel¹, Kenneth Saag⁴, Jeffrey Curtis⁵ and Maria I. ("Maio") Danila⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Tulane University School of Medicine, New Orleans, LA, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Rheumatologists and primary care providers (PCPs) are some of the most trusted clinicians for people living with autoimmune rheumatic diseases (AIRD), and they may…
Abstract Number: 0142 • ACR Convergence 2025
Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Xiaohan Wei¹, Zhixia Yang², Haoyu Pan², Yuying Fan², Jinyi Qian², Shuyi Yu² and Hui Shi³, ¹Shanghai JiaoTong University, Shanghai, China (People's Republic), ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
Abstract Number: 0220 • ACR Convergence 2025
National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration
Alissa Becerril¹, Jing Li², Cherish Wilson³, Gary Tarasovsky⁴, Abimbola Fadairo-Azinge⁵, Mary Whooley⁴ and gabriela Schmajuk⁶, ¹UCSF, san francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴SFVA, San Francisco, ⁵UCSF, San Francisco, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Allopurinol can cause life-threatening severe cutaneous adverse reactions, especially in patients who carry the HLA-B58:01 allele. Because this allele is more common among Southeast…
Abstract Number: 0259 • ACR Convergence 2025
Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
Kristin Highland¹, Colin Reisner², Allison Trucillo³, Deepthi Nair⁴, Felix Woodhead⁴, Howard Lazarus⁴, Craig Conoscenti⁴ and Martin Kolb⁵, ¹Cleveland Clinic, Shaker Heights, OH, ²DevPro Biopharma, Basking Ridge, NJ, ³Avalyn Pharma, Austin, TX, ⁴Avalyn Pharma, Cambridge, MA, ⁵McMaster University, Hamilton, ON, Canada
Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
Abstract Number: 0124 • ACR Convergence 2025
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Haoyu Pan¹, Shiyan Gu¹, Xiaohan Wei², Yuying Fan¹, Jinyi Qian¹, Shuyi Yu¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
Abstract Number: 0267 • ACR Convergence 2025
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
NUR BARLAS¹, Sait Barlas¹ and Emre Adalier², ¹Florida State University College of Medicine, Cape Coral, ²University of Pavia School of Medicine & Surgery, Pavia, Italy
Background/Purpose: Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors have revolutionized treatment for psoriatic arthritis, axial spondyloarthritis, and moderate-to-severe plaque psoriasis. IL-17 inhibitors block the pro-inflammatory cytokine…
Abstract Number: 0003 • ACR Convergence 2025
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Xiaoyu Pan¹, Xiaoning Wang¹, Zhihao Chen¹, Xiaowen Zou¹, Siqi Li¹, Jian Ye¹, Fei Lin¹, Yang He¹, Edo Kon², Peng Zhu¹, Mengyun Chen¹ and Weiyi Zhang¹, ¹RiboX Therapeutics, Shanghai, China (People's Republic), ²RiboX Therapeutics, Cambridge, MA
Background/Purpose: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment and shown promise in addressing autoimmune diseases. However, current ex vivo CAR T-cell therapies…
Abstract Number: 0036 • ACR Convergence 2025
Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus
Mehmet Hocaoglu¹ and Amr Sawalha², ¹University of Pittsburgh Medical Center, Piitsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polygenic risk scores (PRS) have been constructed to summarize genetic risk but there is limited research on environment-wide analysis of risk factors for systemic…
Abstract Number: 0266 • ACR Convergence 2025
Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study
Nanuka Tsibadze¹, Irakli Tskhakaia¹, Rusudan Tskitishvili² and Fabian Rodriguez³, ¹Jefferson Health - Einstein, Philadelphia, PA, ²Virtua Health, Camden, NJ, ³Jefferson Health - Einstein, Philadelphia
Background/Purpose: Proton pump inhibitors (PPIs) are one of the most prescribed medications around the world. Recent research has increasingly identified adverse reactions in patients with…
Abstract Number: 0186 • ACR Convergence 2025
Validation of Asynchronous Telehealth Visit for Adults and Children with Inflammatory Arthritis and Feasibility of Applying Thermal Imaging during Visits
Jenna Thomason¹, Rajdeep Pooni², Erin Sullivan³, Adriel Liau³, Sadie Van den Bogaerde¹, Iris Hamilton³, Sriya Paluvayi³, Megan Tran⁴, Janeth Robles-Navarro⁴, Ian Muse⁵, Audrey Luey⁴, Ava Klein³, Debosmita Biswas⁴, Savannah Partridge⁴, Tzielan Lee⁶, Alison Bays¹, Grant Hughes⁷, Elizabeth Ferucci⁸ and Yongdong (Dan) Zhao⁹, ¹University of Washington, Seattle, WA, ²Stanford University, Berkeley, CA, ³Seattle Children's Hospital, Seattle, ⁴University of Washington, Seattle, ⁵University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷University of Washington, Lynnwood, WA, ⁸Alaska Native Tribal Health Consortium, Anchorage, AK, ⁹Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Use of telemedicine has increased substantially. Our overall goal was to assess the utility of a standardized video joint exam and infrared thermal imaging…
Abstract Number: 0278 • ACR Convergence 2025
Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Xiwei Yang¹, Shae Chambers², Aretha On¹, Hammad Ali², Touraj Khosravi³, Lais Lopes Almeida Gomes², Rui Feng⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy subclassified as classic (CDM) and clinically amyopathic (CADM). It can involve myositis-associated (MAA) and myositis-specific (MSA) autoantibodies.…
Abstract Number: 0006 • ACR Convergence 2025
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
Abstract Number: 0247 • ACR Convergence 2025
Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Elizabeth Volkmann¹, Steven Nathan², Karen Coeytaux³, Yanni Fan⁴, Jill Curran³, Haikun Bao³, Kamila Sroka-Saidi⁵, Ann Chauffe⁶ and Jeffrey J Swigris⁷, ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²Inova Advanced Lung Disease and Transplant Program, Falls Church, VA, USA, Falls Church, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, CT, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA, Denver
Background/Purpose: Nintedanib was approved in the US for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (progressive pulmonary fibrosis [PPF])…
Abstract Number: 0273 • ACR Convergence 2025
Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Synat Keam¹, Yuanteng Li², Yanshuo Chu¹, Jean Tayar³, Huifang Lu⁴, Michael Wu⁵, Sandeep Agarwal⁶, Nitin Jain⁷, Pavlos Msaouel¹, Adi Diab², Cara Haymaker¹, Linghua Wang¹, Roza Nurieva⁸ and Sang Kim⁹, ¹The University of Texas MD Anderson Cancer Center, houston, ²MD Anderson Cancer Center, Houston, TX, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Baylor College of Medicine, Houston, ⁶Baylor College of Medicine, Houston, TX, ⁷The Universty of Texas MD Anderson Cancer Center, Houston, ⁸University of Texas MD Anderson, Houston, TX, ⁹Yale University, Branford, CT
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is associated with life- and/or organ-threatening immune-related adverse events, including inflammatory arthritis (ICI-IA). However, the mechanisms behind ICI-IA, especially…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].